Enovix, Retreat

Enovix Retreat From Smartphone Cells Triggers Analyst Downgrades and Fresh Share Slide

Published on 11/16/2026 at 16:41 | Editorial boerse-global.de
Enovix shares fell 11% after it ended smartphone cell field tests and analysts cut ratings and targets; Q4 2026 revenue is guided to $9.0–10.0 million.
Enovix Retreat From Smartphone Cells Triggers Analyst Downgrades and Fresh Share Slide Illustration mit AI erstellt.

Enovix has spent the week absorbing a double blow: a strategic pullback from smartphone battery testing and a wave of analyst downgrades that sent the stock tumbling further. The shares fell 11% on Friday, following a steeper 18% drop the previous session after the company's quarterly report and forward guidance disappointed investors.

The trigger was Thursday's disclosure that Enovix will not continue field tests of its existing smartphone cells at the system level. According to the company, the cells failed to meet the customer's now-required energy density. Instead, development work with silicon anodes will be redirected toward smart glasses.

Wall Street Slashes Ratings and Targets

Craig-Hallum reacted swiftly, cutting its rating from "Buy" to "Hold" on Friday, citing the provisional withdrawal and persistent production hurdles, according to media reports. The firm also slashed its price target from $7 to $2. Oppenheimer followed suit that same day, downgrading Enovix from "Outperform" to "Perform" and pointing to the departure from smartphone battery testing and the sharper focus on drones and smart glasses. A third research house also moved to a neutral rating on Friday, with its price target dropping from $9 to $2.

Guidance and Quarterly Results Underpin the Selloff

The outlook published Thursday, alongside the quarterly figures, was among the catalysts for the selloff. For the fourth quarter of 2026, Enovix projects revenue of $9.0–10.0 million. For full-year 2027, the company guided to revenue of $65.0–85.0 million.

Should investors sell immediately? Or is it worth buying Enovix?

In the third quarter of 2026, Enovix generated revenue of $11 million, representing growth of 38% year over year on a company-reported basis. Non-GAAP gross margin came in at 34.5%, while the adjusted loss per share was $0.15. The net loss attributable to Enovix narrowed to $41.9 million, down from $53.7 million in the prior-year quarter.

At quarter-end, cash, cash equivalents, marketable securities and restricted cash totaled $512.2 million — a figure that includes not only freely available funds but also other asset positions.

Restructuring Shifts Resources Toward Korea

Alongside the quarterly numbers, Enovix detailed a restructuring implemented in early November that eliminated 220 positions. Annual costs fell by roughly $8.5 million, according to the company, as resources were redirected more heavily toward its operations in Korea.

Enovix at a turning point? This analysis reveals what investors need to know now.

The cost-cutting plan's first phase and an expanded emphasis on defense-application batteries had already been announced on November 5. That disclosure included a $19 million investment aimed at doubling the company's drone battery capacity in South Korea — an expansion targeting a different application area than the smartphone business.

The combination of a customer-driven product setback, steeply reduced analyst targets and cautious near-term guidance has left investors reassessing the company's transition toward defense and wearable applications.

Ad

Enovix Stock: New Analysis - 16 November

Fresh Enovix information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Enovix analysis...

Disclaimer...
en | US2935941078 | ENOVIX | boerse | 70521621 |